![](https://www.acsh.org/sites/default/files/articles/screenshot-2024-07-10-at-3.17.27-pm.png)
HilleVax Norovirus Vaccine Spits (Up) the Bit
Another norovirus vaccine bites the dust. This time, it's HilleVax's HIL-214, which provided an appalling 5% efficacy in Phase 2B trials in infants. The kids got sick, but perhaps the stockholders got even sicker. You'll see why. For many years …